A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
Completed · Phase 1
Conditions studied: Alopecia Areata
In brief
The purpose of the study is to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called Ritlecitinib) in children of 6 to \<12 years of age with Alopecia Areata, a condition of scalp hair loss. 12 children with alopecia areata will be participating in this study. All participants will receive study medicine with a dose of 20 milligram (mg) orally once daily for 7 days. 5 blood samples will be collected on day 7 for pharmacokinetic evaluation and 2 blood samples each at screening and on Day 7 will be collected for pharmacodynamic evaluation. Participants will take part in the study for about 10 weeks.
Key facts
- Study ID
- NCT05650333
- Run by
- Pfizer
- People needed
- 15
- Starts
- 2023-03-02
- Expected to finish
- 2023-08-11
- Last updated by the study team
- 2024-10-08
Who can join
Age: 6 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Dermatology & Clinical Research Institute — Encinitas, California, United States
- Pediatric Skin Research,LLC — Coral Gables, Florida, United States
- Nicklaus Children's Hospital — Miami, Florida, United States
- Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
- University of New Mexico Health Sciences Center — Albuquerque, New Mexico, United States
- UNMH — Albuquerque, New Mexico, United States
- Vital Prospects Clinical Research Institute, PC — Tulsa, Oklahoma, United States
- Northwest Dermatology Institute — Portland, Oregon, United States
- Texas Dermatology and Laser Specialists — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.